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Max Planck proclaimed that ‘science cannot solve the
ultimate mystery of nature . . . ’ and that was—in his
opinion—since ‘we are part of the mystery we try to
solve’. Most will agree with the first part of the state-
ment; the question is what he meant with the second.
The problem with the ‘nature’ that is the subject of
clinical research is that it is quite complex and that
we have limited technical tools and understanding to
grasp that convoluted reality.
The study by van Lavieren et al. is an illustration
thereof [1]. The relationship between admission glu-
cose level in non-diabetic patients with a first ST-seg-
ment elevationmyocardial infarction (STEMI) andmi-
crovascular function of the infarct-related (IRA) and
non-infarct (reference) artery was studied. For that
purpose, coronary flow velocity reserve (CFVR) was
calculated of the IRA and reference vessel, of which
the baseline (BMR) and hyperaemic (HMR) microvas-
cular resistance was also calculated provided the per-
centage diameter stenosis was <30%. The article by
van Lavieren et al. concerns an observational study
with its inherent and acknowledged limitations (e.g.
sample size, inclusion and exclusion criteria, incom-
plete follow-up, glucose level measured only once at
admission without further biochemical details of glu-
cose metabolism) using unadjusted and adjusted lin-
ear regression. The main finding was an absence of
such an association in the IRA but a lower CFVR with
increasing glucose level in the reference vessel plau-
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sibly due to a combination of a higher flow and lower
resistance at baseline.
In other words, while during acute percutaneous
coronary intervention (PCI) all our attention is fo-
cused on the IRA, microvascular dysfunction occurs at
remote sites of the heart that may need our attention
since there may be prognostic implications. This en-
deavour must be applauded, as it concerns a study of
complex methodology that adds insight into a poorly
known pathophysiological process and thus may help
to propose adjunctive measures to improve the effi-
cacy of treatment.
Biological processes, however, are multidimen-
sional and thus linear regression may fail to elucidate
the complex associations of factors that play a role
in outcome (i.e. microvascular function). This is
not only a sample size issue (see regression line and
slope in the scatter plot) but more importantly that
relationships in biological processes may be non-
linear. Also, the nature of the association remains
unclear (cause-and-effect, indirect, epiphenomenon,
etc.). Albeit subject to debate, factors other than sec-
ondary acute stress-related biochemical factors may
play a role as well as indicated by the multivariate
regression (heart rate, changes in regional myocardial
wall tension). Interestingly, in an attempt to elucidate
the pathophysiology of microvascular (dys)function
during STEMI, the answer to the original hypothesis
generates novel hypotheses. Instead of focussing on
biochemical reactions and consequently counteract-
ing these (e.g. by GIK administration) unloading of
the myocardium may eventually be more beneficial
[2].
Tijssen et al. report the circa 4-year outcomes of
135 patients enrolled in the AMC Absorb Registry
(2012–2013) who were treated with a bioresorbable
vascular scaffold (BVS) for stable or unstable coro-
nary artery disease (both roughly 50%) [3]. The au-
Clinical science, responsibilities and society 113
Commentary
thors postulate real-world practice but selection bias
cannot be ruled out since the decision to implant
a BVS was left to the discretion of the operator. Also,
the total number of patients treated with PCI during
that period is not mentioned. The 4-year cumulative
cardiac death rate, target-vessel myocardial infarction
and target-vessel revascularisation (TVR) were 3.2%,
6.9% and 16.7%, respectively. Target lesion revascu-
larisation (included in or excluded from TVR?) was
14.6% and the incidence of ‘definite’ scaffold throm-
bosis was 3.8% (one case at 911 days in a patient with
stable angina and type A lesion). Given that follow-
up was by telephone contact and status examination,
these point estimates—except for death—likely rep-
resent an underestimation of their true value. More
importantly, the Kaplan-Meier curve reveals a contin-
uous occurrence during the entire follow-up period,
albeit most cases occur within 18 months after BVS
implantation. The authors rightfully conclude that
events ‘continue to accrue beyond two years’.
There is little discussion that, when PCI is indi-
cated, the ideal treatment consists of the implanta-
tion of a non-permanent device (scaffold). Yet, given
the findings of Tijssen et al. and those of randomised
controlled trials, one may question whether the tech-
nology is ready for use notwithstanding its approval
(EU, US authorities). As suggested by the authors,
procedure-/operator-related factors may play a role.
The role of proper sizing (plus length) and implan-
tation technique was shown soon after the introduc-
tion of the permanent scaffold (stent) [4]. Yet, out-
come is also determined by patient-related variables
as indicated by the ABSORB II and III trials (i.e. lower
event rate when excluding patients with acute coro-
nary syndrome and complex lesions) and device-re-
lated factors [5, 6]. The implantation of a BVS is in-
variably associated with reactive (e.g. inflammatory)
vessel wall responses that are still incompletely un-
derstood in terms of nature and time course. It, thus,
appears that BVS technology should only be used in
clinical trials with strict and independent analysis and
surveillance.
Pustjens et al. have published an elegant position
paper concerning the management of patients with
acute myocardial infarction (MI) and non-obstructive
coronary artery disease (MINOCA) [7]. The article
concerns a difficult clinical entity given that the def-
inition of MI is subject to interpretation and given
the many cardiac and non-cardiac conditions possi-
bly associated with MINOCA. Some can be diagnosed
easily and accurately, others cannot (most often car-
diac conditions) due to technical issues and issues of
sensitivity, specificity, etc. In addition, the causative
relationship between finding and clinical presentation
may be doubtful. The authors provide a well-designed
diagnostic algorithm stressing that it concerns a dy-
namic working diagnosis. This paper nicely illustrates
the complexity of the mystery that we try to solve, as
well as the limited insight we still have despite the
many technical tools.
Zwart et al. published an interesting paper on the
management of patients with non-ST-segment eleva-
tion acute coronary syndromes (NSTE-ACS) as they
draw our attention to which patients are truly at high
risk and merit early/urgent revascularisation (GRACE
>140) and by fine-tuning the ESC guidelines to the
Dutch context with its typical geography, high level of
care and organisation [8]. Most patients with NSTE-
ACS are indeed not truly at high risk and, therefore,
same-day transfer to a PCI centre can be avoided. In
these patients further and appropriate treatment de-
cisions can be taken by the heart team incorporating
relevant patient-related factors (e.g. age, antecedents,
co-morbidity, etc.) in combination with the coronary
anatomy.
Consequently, the physician and sound clinical
sense are reinstated as the imperative safeguard of
the appropriateness of care. What is needed, how-
ever, is a reassessment of how the organisation of
care in the Netherlands needs to be adapted to these
insights. It can be argued that organisational effi-
ciency has become the main driver of the execution
of care (i.e. quick turn-over) rather than the selection
of treatment and timing that best fits the individual
patient. This stems from the policy during the 1990s
by which medicine came to be considered a commer-
cial product in combination with cost containment,
whereby the replacement of hospitals by medical
centres was in part followed by a reduction in the
numbers of paramedics and beds. The key word is
time. Time is money, the more time we take (back) as
professionals, the more appropriate and, conceivably,
more cost-effective will be the delivery of care.
The beauty of peer-reviewed journals such as the
Netherlands Heart Journal is that after revision and
more distant reflection, as yet unnoticed concepts
may emerge, stimulating further thinking and re-
search in our quest to ‘solve the mystery of nature’
and to deliver care as best we can, whereby hospital
management and authorities have a responsibility as
well.
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